PD15-10 FEASIBILITY OF HIFU-TRIGGERED SORAFENIB-LOADED LIPOSOME NANOPARTICLES FOR TARGETED DRUG THERAPY IN RENAL CELL CARCINOMA

2015 ◽  
Vol 193 (4S) ◽  
Author(s):  
Caleb Abshire ◽  
James Liu ◽  
Jaspreet Arora ◽  
Hakm Murad ◽  
Sree Harsha Mandava ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Drug Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Targeted Drug

scholarly journals Embelin Enhances the Sensitivity of Renal Cancer Cells To Axitinib by Inhibiting HIF-1α Signaling Pathway

2021 ◽  
Author(s):  
Qiong Fang ◽  
Zhiying Li ◽  
Ye Xue ◽  
Xin Zong ◽  
Wenshuang Ma ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Cells ◽  
Renal Cancer ◽  
Renal Cell ◽  
High Recurrence Rate ◽  
Urinary System ◽  
Regulatory Pathways ◽  
Targeted Drug ◽  
Clinical Drugs

Abstract Background Renal cell carcinoma (RCC) is a common malignant tumor of urinary system with high recurrence rate and easy metastasis. Current clinical drugs for renal cell carcinoma include immunotherapy and targeted drugs. Axitinib is a clinical targeted drug for the treatment of renal cell carcinoma, which has some shortcomings such as unstable efficacy and easy drug resistance. The aim of this study was to determine whether embelin can enhance the sensitivity of renal cancer cells to axitinib and explore its regulatory pathways. Results Embelin enhanced the sensitivity of renal cancer cells to axitinib in the following aspects: enhancing the inhibition of cell proliferation by axitinib, the ability to kill cancer cells, and the induction of cell apoptosis. HIF-1α was a potential pathway of Embelin action. After IOX2 regulated the HIF-1α pathway, the enhancing effect of embelin on axitinib was weakened. Conclusions Embelin enhanced the sensitivity of both A498 and 786-O renal cancer cells to axitinib by inhibiting the HIF-1α pathway.

scholarly journals Tumor-derived exosomes facilitate tumor cells escape from drug therapy in clear cell renal cell carcinoma

2020 ◽  
Vol 9 (5) ◽  
pp. 3416-3425
Author(s):  
Xiaogang Wang ◽  
Qianqian Shi ◽  
Li Cui ◽  
Kai Wang ◽  
Pengfeng Gong ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Drug Therapy ◽  
Cell Carcinoma ◽  
Tumor Cells ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma

scholarly journals RNF43 is a Novel Tumor Suppressor and Prognostic Indicator in Clear Cell Renal Cell Carcinoma

2021 ◽  
Author(s):  
Dawei Zhu ◽  
Lei Zhang ◽  
Xiaokai Shi ◽  
Shenglin Gao ◽  
Chuang Yue ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Suppressor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Prognostic Indicator ◽  
Cell Renal Cell Carcinoma ◽  
Targeted Drug

Identifying prognostic indicators of clear cell renal cell carcinoma (ccRCC) and elucidating the mechanisms underlying ccRCC progression are crucial for improving ccRCC patient prognosis. This study investigated the clinical significance and biological role of Ring finger protein 43 ( RNF43) in ccRCC. Two independent cohorts of patients with ccRCC were employed to determine the prognostic significance of RNF43 by immunohistochemistry and statistical analyses. In vitro and in vivo experiments, RNA-seq, and other techniques were used to determine the biological role of RNF43 in ccRCC and related molecular mechanisms. RNF43 expression was commonly decreased in ccRCC specimens, and low expression of RNF43 indicated a higher TNM stage, SSIGN score, and WHO/ISUP grade and short survival in patients with ccRCC. Additionally, RNF43 overexpression suppressed the proliferation, migration, and targeted drug resistance of ccRCC cells, while the knockdown of RNF43 enhanced these characteristics of ccRCC. RNF43 knockdown activated YAP signaling by decreasing YAP phosphorylation by p-LATS1/2 and increasing the transcription and nuclear distribution of YAP. By contrast, RNF43 overexpression showed the opposite effects. Decreasing YAP abolished the effect of RNF43 knockdown in promoting the malignant features of ccRCC. Additionally, restoring RNF43 expression suppressed the resistance of the targeted drug pazopanib in in vivo orthotopic ccRCC. Furthermore, combining the expression of RNF43 andYAP with TNM stage or the SSIGN score exhibited greater accuracy than any of these indicators alone in assessing the postoperative prognosis of ccRCC patients. In summary, our study identified a novel tumor suppressor, RNF43, which is also a prognostic indicator and potential target for ccRCC potential target for ccRCC.

Pharmacist-led monitoring program for patients on sunitinib for metastatic renal-cell carcinoma: A Canadian experience.

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 479-479
Author(s):  
Scott Edwards ◽  
Lori Wood ◽  
Joy S. McCarthy ◽  
Andrew Collins ◽  
Lynn Hartery ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Drug Therapy ◽  
Oral Cancer ◽  
Treatment Failure ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Monitoring Program ◽  
Time To Treatment ◽  
Time To Treatment Failure ◽  
Dose Reductions

479 Background: Sunitinib is a standard of care for first-line treatment of metastatic clear cell renal-cell carcinoma (mRCC). Despite having a relatively good safety profile, Sunitinib does have several clinically important toxicities. With the rapid rise in the use of Sunitinib and other oral cancer agents, we instituted a pharmacist-led monitoring program in the ambulatory care setting to prospectively document, monitor, and manage toxicities in our Canadian province. Methods: The pharmacist-led monitoring program consisted of patient assessments in clinic with the oncology team combined with a call back program. The program consisted of a patient assessment in the oncology clinic on day 1 of a Sunitinib cycle followed with a call back on day 14. A chart review of consecutive patients who were prospectively monitored by this progam after receiving Sunitinib for mRCC was conducted. Treatment specific data for the first six cycles of therapy included dose reductions, therapy delays/interruptions, therapy discontinuation, and reason for each was recorded. Toxicity data including the occurrence and severity grade was collected. The time to treatment failure (TTF) defined as the time from therapy initiation to treatment discontinuation for any reason was measured. Results: Fifty six patients are included in the study cohort. Of these, 52 (92.86%) started at the standard 50 mg once daily and the remainder at a reduced dose. Additionally, 15 patients experienced hypertension requiring drug therapy adjustment or additional antihypertensive therapy. Two patients required drug therapy for hypothyroidism. There were a total of 39 dose reductions in this patient population over a six cycle period. The majority of dose reductions (46.2%) and therapy interruptions (34.5%) occurred during cycle one. The time to treatment failure for the 45 patients that discontinued therapy was 9.72 months. Conclusions: Pharmacist-Led monitoring of oral cancer therapies is a practical and feasible method of monitoring patients on Sunitinib for mRCC. The success has led to its implementation with other agents and disease sites.

Sign in / Sign up

Export Citation Format

Share Document